

1 **Title:** Epigenetic programming of host lipid metabolism associates with resistance to TST/IGRA
2 conversion after exposure to *Mycobacterium tuberculosis*

3 **Running title:** Host lipid epigenetics and exposure to tuberculosis

4

5 Kimberly A Dill-McFarland^a#, Jason D Simmons^a, Glenna J Peterson^a, Felicia K Nguyen^a, Monica
6 Campo^{a*}, Penelope Benchek^b, Catherine M Stein^{b,c}, Tomas Vaisar^a, Harriet Mayanja-Kizza^d, W
7 Henry Boom^c, Thomas R Hawn^a

8

9 ^a Department of Medicine, University of Washington, Seattle, WA, USA;

10 ^b Department of Population and Quantitative Health Sciences, Case Western Reserve University,
11 Cleveland, Ohio, USA;

12 ^c Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

13 ^d Department of Internal Medicine, Makerere University, Kampala, Uganda;

14 * Current affiliation: Department of Medicine, University of Minnesota, Minneapolis, MN, USA

15

16 **Correspondence to:**

17 Kimberly A Dill-McFarland

18 kadm@uw.edu

19

20 **ABSTRACT**

21 *Mycobacterium tuberculosis* (Mtb) exposure leads to a range of outcomes including clearance,
22 latent TB infection (LTBI), and pulmonary tuberculosis (TB). Some heavily exposed individuals
23 resist tuberculin skin test (TST) and interferon gamma release assay (IGRA) conversion (RSTR),
24 which suggests that they employ IFNy-independent mechanisms of Mtb control. Here, we
25 compare monocyte epigenetic profiles of RSTR and LTBI from a Ugandan household contact
26 cohort. Chromatin accessibility did not differ between uninfected RSTR and LTBI monocytes. In
27 contrast, methylation significantly differed at 174 CpG sites and across 63 genomic regions.
28 Consistent with previous transcriptional findings in this cohort, differential methylation was
29 enriched in lipid and cholesterol associated pathways including in the genes APOC3, KCNQ1,
30 and PLA2G3. In addition, methylation was enriched in Hippo signaling, which is associated with
31 cholesterol homeostasis and includes CIT and SHANK2. Lipid export and Hippo signaling
32 pathways were also associated with gene expression in response to Mtb in RSTR as well as IFN
33 stimulation in monocyte-derived macrophages (MDMs) from an independent healthy donor
34 cohort. Moreover, serum-derived HDL from RSTR had elevated ABCA1-mediated cholesterol
35 efflux capacity (CEC) compared to LTBI. Our findings suggest that resistance to TST/IGRA
36 conversion is linked to regulation of lipid accumulation in monocytes, which could facilitate
37 early Mtb clearance among RSTR subjects through IFNy-independent mechanisms.

38

39 **IMPORTANCE**

40 Tuberculosis (TB) remains an enduring global health challenge with millions of deaths and new
41 cases each year. Despite recent advances in TB treatment, we lack an effective vaccine or a

42 durable cure. While heavy exposure to *Mycobacterium tuberculosis* often results in latent TB
43 latent infection (LTBI), subpopulations exist who are either resistant to infection or contain Mtb
44 with IFN γ -independent mechanisms not indicative of LTBI. These resisters provide an
45 opportunity to investigate mechanisms of TB disease and discover novel therapeutic targets.
46 Here, we compare monocyte epigenetic profiles of RSTR and LTBI from a Ugandan household
47 contact cohort. We identify methylation signatures in host lipid and cholesterol pathways with
48 potential relevance to early TB clearance before the sustained IFN responses indicative of LTBI.
49 This adds to a growing body of literature linking TB disease outcomes to host lipids.

50

51 INTRODUCTION

52 Tuberculosis (TB) remains one of the leading causes of single-agent infectious disease death
53 worldwide with over 1 in 1000 people developing new TB and 1.4 million deaths annually (1).
54 Individuals infected with *Mycobacterium tuberculosis* (Mtb), the causative agent of TB, exhibit a
55 range of clinical phenotypes from latent Mtb infection (LTBI) to pulmonary TB disease. LTBI,
56 defined as a positive tuberculin skin test (TST) or interferon (IFN)- γ release assay (IGRA) with no
57 clinical or radiographic evidence of TB disease, describes as much as a quarter of the world's
58 population (2). Some individuals resist TST/IGRA conversion (RSTR) despite prolonged and high-
59 level Mtb exposure (3–6). Many factors likely contribute to resistance to TST/IGRA conversion
60 including genetics, previous *Mycobacterium* infections, lung function, and others (7). We and
61 others previously found differences in immunologic profiles of RSTR and LTBI subjects (5),
62 including transcriptional signatures in monocytes (8, 9). Further investigation of RSTR

63 populations may yield novel insights into host responses to Mtb and identify IFNy-independent
64 correlates of protection or targets for TB therapeutics.

65

66 Epigenetic mechanisms may regulate transcriptional responses and contribute to RSTR
67 mechanisms. Methylation has been associated with the risk of LTBI conversion (10, 11), anti-
68 mycobacterial activity (12–14), and response to Bacille Calmette-Guérin (BCG), a vaccine for TB
69 disease in children (15). As one of Mtb's first targets in the lung, macrophages are poised to
70 accomplish early Mtb clearance through cell intrinsic microbicidal pathways or by priming IFNy-
71 independent cellular responses, both of which may operative in the absence of TST/IGRA
72 conversion (16, 17). Some macrophage responses to Mtb infection *in vitro* are modulated
73 through methylation (18), and monocyte responses to BCG have been associated with
74 chromatin remodeling (19). We also previously found that histone deacetylases (HDAC) were
75 differentially expressed in RSTR monocytes compared to LTBI in a Ugandan household contact
76 study (20) and that an HDAC3 inhibitor modulated macrophage signaling during Mtb infection
77 (21). Together, these studies suggest that epigenetic “trained immunity” may regulate Mtb
78 clearance without TST/IGRA conversion.

79

80 In this study, we further characterize immune pathways in a Ugandan RSTR cohort consisting of
81 household contacts of pulmonary TB cases who remain TST/IGRA-negative over 8 - 10 years (3,
82 22). Genome-wide methylation and chromatin accessibility were assessed in unstimulated RSTR
83 and LTBI monocytes. Orthogonal to RSTR transcriptional signatures identified previously (8, 9),

84 we identify methylation signatures in lipid and cholesterol pathways with potential relevance to
85 IFN responses and macrophage function during Mtb infection.

86

87 **RESULTS**

88 **RSTR methylation differs in lipid and cholesterol associated genes compared to LTBI.** We
89 examined chromatin accessibility and methylation in monocytes from RSTR and LTBI individuals
90 (Table 1). RSTR and LTBI groups did not differ by sex, age, body mass index (BMI), BCG
91 vaccination scar, TB exposure score at enrollment (3), or relatedness as measured by total first-
92 and third-degree or closer relationships between each individual and all other individuals in the
93 dataset ($P > 0.05$). All participants were HIV negative.

94

95 Epigenetic signals were tested using a linear mixed effects model for RSTR vs LTBI corrected for
96 age, sex, and genetic kinship (Figure S1). Two differentially accessible regions (DAR) and 174
97 differentially methylated probes (DMP) were identified between RSTR and LTBI at $FDR < 0.2$
98 (Figure 1 A,B, Table S1). DMP were then used to define 63 differentially methylated regions
99 (DMR) ($FDR < 1E-70$) (Figure 1C) each containing two to seven probes (Table S1). In total, 44 of
100 the 63 DMR contained at least one DMP site (Table S1). Significant DAR annotated to one gene
101 (CAMK1D) and an intergenic region. DMP annotated to 125 genes and DMR to 44 genes.
102 Significant epigenetic sites included 40 DMPs and 18 DMRs annotated to promoter regions
103 within 1500 bp of a transcription start site (TSS1500) (Figure S2). Together, these data suggest
104 that RSTR and LTBI monocytes contain distinct epigenetic profiles long after their initial Mtb
105 exposure.

106

107 To assess for connections among the methylation genes, we used hypergeometric mean
108 pathway enrichment analysis with Broad MSigDB gene-sets (23). DMR genes were enriched in
109 11 gene ontology (GO) pathways (FDR < 0.2 and k/K > 0.04, Table S2). No Hallmark gene-sets
110 were significantly enriched, and neither database was enriched within DMP genes. The most
111 highly enriched GO gene-sets for DMR were associated with high-density lipoprotein (HDL)
112 remodeling, lipid export, fatty acid biosynthesis, and Hippo signaling (Figure 2A). Nine DMRs
113 annotated to 8 unique genes (APOC3, CIT, KCNQ1, MCM2, PER3, PLA2G3, RPTOR, SHANK2)
114 drove significant enrichments (Figure 2B, Table S3).

115

116 Among genes enriched in fatty acid, lipid, and HDL pathways (Figure 3A,B), APOC3, KCNQ1, and
117 PLA2G3 each contained one DMR in their TSS1500 region. APOC3 had consistently higher
118 methylation while PLA2G3 had consistently lower methylation as well as a significant DMP site
119 (asterisk) in RSTR compared to LTBI (Figure 3A). In contrast, KCNQ1 had discordant DMR
120 methylation and was driven by a single DMP site with higher methylation in RSTR (asterisk,
121 Figure 3A). Among Hippo signaling associated genes (Figure 3C,D), CIT contained one TSS1500
122 DMR driven by a single DMP site with higher methylation in RSTR compared to LTBI (asterisk,
123 Figure 3C). SHANK2 contained two intronic DMRs both with consistently lower methylation in
124 RSTR compared to LTBI (Figure 3C,D). Together, these data suggest that methylation signatures
125 differentiate RSTR and LTBI monocytes with profiles related to lipid and cholesterol processes.

126

127 Utilizing a previously published transcriptomics study of this same cohort (9), we next
128 investigated the impacts of Mtb infection on gene expression related to methylation signatures.
129 Among lipid and HDL-associated genes identified in the methylation analysis (Figure 2), APOC3
130 and PLA2G3 were significantly upregulated while KCNQ1 was downregulated in response to
131 Mtb infection in monocytes (Figure 3E). For Hippo signaling genes, CIT was upregulated and
132 SHANK2 was downregulated after Mtb infection (FDR < 0.05) (Figure 3F). None of these
133 selected genes had differential expression between RSTR and LTBI groups (FDR > 0.2) (Figure
134 3E,F). Gene-set enrichment analysis (GSEA) further revealed that the lipid export gene-set was
135 upregulated by Mtb infection in both RSTR and LTBI monocytes with the highest expression
136 among Mtb-infected RSTR monocytes ($P < 0.05$, Figure 4A, Table S4). While GSEA suggested
137 Hippo signaling was not significantly impacted by Mtb infection (FDR > 0.05), RSTR Mtb-infected
138 monocytes had higher Hippo signaling gene expression compared to LTBI (FDR < 0.05, Figure
139 4A, Table S4). Thus, methylation signatures in uninfected monocytes correlate with Mtb-
140 dependent gene expression patterns that distinguish RSTR from LTBI.

141
142 **Interferon-specific lipid transcriptional responses in MDM.** Given that RSTR and LTBI
143 phenotypes are defined by Mtb-specific IFN γ responses, we next explored IFN-dependent gene
144 expression in pathways associated with methylation. We looked for overlapping enrichment
145 between methylation associated gene-sets described above and the transcriptional responses
146 of an independent healthy cohort's MDMs to Type I and Type II interferons (24). Among the 11
147 methylation-enriched GO gene-sets, lipid export was significantly up-regulated by IFN α 8
148 stimulation in healthy MDMs ($P < 0.05$, Figure 4B, Table S4). We then utilized the STRING

149 protein-protein interaction network to visualize all genes in the GO lipid export gene-set and
150 determine overlap between methylation and transcriptional signatures (Figure 4C). The leading-
151 edge genes for each enrichment analysis were colored to identify genes with differential
152 methylation in RSTR (DMR gene) that likely drive expression changes in RSTR compared to LTBI
153 (RSTR), in response to Mtb infection (Mtb), and/or in response to IFN stimulation (IFN α 8, IFN γ ,
154 IFN other). As seen in the STRING network (Figure 4C), IFN α 8 enrichment was driven by 13
155 leading-edge genes that mostly overlapped with leading-edge genes in the non-significant
156 interferon stimulations (12/13, Figure 4D). This MDM IFN α 8 leading-edge also overlapped with
157 leading-edge genes for lipid export in response to Mtb (8/13) and RSTR compared to LTBI in
158 Mtb infected monocytes (3/13). Together, these data suggest that epigenetic programming
159 may impact lipid export pathways that lead to differences in RSTR and LTBI responses to Mtb
160 infection and may be modulated by IFN induced responses.

161
162 In addition, the methylation-enriched Hippo signaling gene-set, which contributes to
163 cholesterol homeostasis (25), was up-regulated by IFN γ ($P < 0.05$, Figure 4B). As visualized in
164 the STRING network (Figure 4D), Hippo signaling in MDMs had 14 leading-edge genes that
165 mostly overlapped with nonsignificant IFN stimulations (12/14) and somewhat overlapped with
166 the RSTR compared to LTBI leading-edge in Mtb infected monocytes (3/13) (Figure 4D). Overall,
167 these data indicate that epigenetically programmed pathways related to Hippo and cholesterol
168 may be impacted by IFN γ induced responses that define RSTR and LTBI phenotypes.

169

170 **Cholesterol efflux capacity of HDL differs between RSTR and LTBI.** To examine lipid-dependent
171 mechanisms of RSTR clearance of Mtb, we next measured serum HDL particle concentrations
172 and sizes as well as cholesterol efflux capacity (CEC) of serum HDL from RSTR and LTBI
173 individuals. Neither HDL particle concentrations nor sizes (xsHDL to xIHDL) differed between
174 unstimulated RSTR and LTBI serum (Figure S3, Table S5, FDR > 0.2). RSTR and LTBI serum HDL
175 had similar total CEC with cAMP activation to stimulate efflux in mouse J774 macrophages (6.1
176 \pm 1.9 %, P > 0.05, Figure 5A, Table S5). In contrast, ABCA1-specific CEC in BHK cells was higher
177 with RSTR serum HDL compared to LTBI (Δ LTBI = 6.2 \pm 2.1 %, Δ RSTR = 7.5 \pm 2.8 %, P = 0.02)
178 with no differences in unstimulated cells (Figure 5B, Table S5). Moreover, investigation of the
179 previously published transcriptomics study of this same cohort (9) revealed differential
180 expression of ABCA1 in monocytes upon Mtb infection with RSTR displaying significantly higher
181 induction compared to LTBI (Figure 5C). Together, the complimentary effects of increased CEC
182 and ABCA1 may reduce intracellular cholesterol levels during infection and contribute to IFN γ -
183 independent Mtb control in RSTR.

184

185 **DISCUSSION**

186 We assessed monocyte methylation and chromatin accessibility signatures in latent
187 tuberculosis infection (LTBI) and IGRA/TST resistant individuals (RSTR). We found differential
188 methylation in genes related to high-density lipoprotein (HDL) remodeling, lipid export, and
189 fatty acid metabolism. In addition, ABCA1-mediated HDL cholesterol efflux capacity (CEC) was
190 higher in RSTR compared to LTBI. These results contribute to the growing body of literature

191 supporting the importance of host lipid and fatty acid metabolism in *Mtb* infection and disease
192 progression (8, 26).

193
194 RSTR had distinct methylation patterns compared to LTBI in genes associated with fatty acid
195 metabolism and lipid transport. These genes included the phospholipase PLA2G3 (27) and
196 lipase repressor APOC3 (28), which associate with HDL and impact intracellular lipid availability.
197 Specifically, an overabundance of APOC3 may reduce HDL-mediated CEC, potentially through
198 competitive binding to the scavenger receptor SCARB1 (29). In addition, the lipid-mediated
199 voltage-gated potassium channel KCNQ1 contained methylation signatures in RSTR. Several
200 KCNQ1 mutations are associated with plasma lipid accumulation (30), and KCNQ1's antisense
201 lncRNA, KCNQ1OT1, is associated with reduced CEC and increased lipid accumulation in
202 macrophages specifically (31). These lipase and lipid transport activities impact free fatty acid
203 (FFA) availability and contribute to the accumulation of lipids. This can lead to lipid-laden, or
204 foamy, macrophages which are a permissive environment for *Mtb* persistence (32–34). In fact,
205 PLA2G3 directly promotes foamy macrophage accumulation in mice (27). The importance of
206 FFAs in the RSTR phenotype is further supported by previous work in this Ugandan as well as an
207 independent South African cohort, where gene-sets associated with FFA metabolism were
208 more highly expressed in unstimulated RSTR monocytes compared to LTBI (35). Finally, lipid
209 transport after *Mtb* infection may be further regulated by IFN signaling, a defining feature of
210 RSTR, as indicated by upregulation of lipid export gene expression in response to *Mtb* infection
211 in RSTR monocytes and to IFN α 8 in monocyte-derived macrophages (MDMs). Thus, differences
212 in RSTR methylation in FFA metabolism and lipid transport genes correlate with transcriptional

213 signatures and suggest that epigenetic programming may control lipid accumulation, thus
214 ultimately preventing Mtb persistence.

215
216 The RSTR phenotype may be additionally mediated by cholesterol as indicated by the previously
217 discussed lipid-associated genes (PLA2G3, APOC3, KCNQ1) as well as additional methylation hits
218 related to Hippo signaling (CIT, SHANK2). Cholesterol represents an important fatty acid for Mtb
219 as it is a preferred carbon source (32, 34) and contributes to macrophage responses to Mtb
220 including membrane lipid rafts permissive to Mtb uptake (36), modulation of cellular function,
221 and development of foamy macrophages (32, 33, 37, 38). Hippo signaling is involved in
222 pleiotropic activities related to cell proliferation, differentiation, and survival (25) including in
223 macrophages (39). Among these functions, Hippo signaling regulates cholesterol levels through
224 sterol regulatory element-binding proteins (SREBPs) (25). We previously identified enrichments
225 in IFN γ signaling that discriminated LTBI from RSTR monocytes (8, 9), an expected finding based
226 on categoric IGRA responses (3, 22). Paradoxically, Hippo signaling expression was increased
227 with IFN γ stimulation in healthy MDMs but associated with Mtb-infected RSTR monocytes. This
228 suggests that Hippo signaling is activated among RSTR and may provide protection against Mtb
229 infection in the absence of IFN γ (3, 22). We further investigated RSTR links to cellular
230 cholesterol by measuring CEC. RSTR serum HDL resulted in higher ABCA1-mediated cholesterol
231 efflux compared to LTBI, thus supporting that RSTR are better able to control intracellular
232 cholesterol accumulation. Together, these findings support a hypothesis that Mtb growth is
233 restricted among RSTR monocytes due to enhanced CEC that leads to decreased intracellular

234 (40) or membrane (36) cholesterol with CEC potentially regulated by ABCA1 and/or Mtb-
235 induced Hippo signaling as a result of specific methylation signatures.

236

237 Our study has several limitations. The peripheral blood monocytes investigated in this study
238 represent an important cell population relevant to TB disease. However, epigenetic profiles in
239 lung resident cell populations such as alveolar macrophages may reveal additional markers of
240 the RSTR phenotype. Additionally, while methylation is known to alter gene expression, the
241 impacts of hyper- vs hypomethylation are not clear for gene expression directionality or
242 association with disease (41, 42). Therefore, a more complete analysis of RSTR with paired
243 methylation and gene expression in Mtb-infected cells is needed to elucidate the impacts of
244 methylation on Mtb-relevant gene expression. This design may also reveal differences in
245 chromatin accessibility not captured in the current dataset from uninfected cells. While
246 methylation remains relatively stable over time, changes can occur on the time scale of years to
247 decades (43). This RSTR cohort was defined by long-term follow-up spanning up to 10 years.
248 Thus, the epigenetic markers of this stringently defined RSTR phenotype that was sampled long
249 after documented exposure may not fully capture mechanisms relevant to Mtb clearance at the
250 time of exposure. Finally, these findings are based on a single RSTR cohort, and epigenetic
251 inquiry into additional cohorts with varied RSTR definitions is needed to confirm findings
252 applicable to a larger population.

253

254 Overall, these results indicate that RSTR have distinct epigenetic programming related to lipid
255 and cholesterol transport in monocytes. Differentially methylated genes in RSTR and LTBI likely

256 lead to differences in lipid accumulation in monocytes and this, in turn, may alter Mtb
257 outcomes and contribute to IFN γ independent control of Mtb in RSTR. Together with previous
258 work in this cohort (8, 9, 44), this study supports the role of lipid and fatty acid metabolism in
259 defining the Ugandan RSTR cohort as well as provides novel targets for the development of TB
260 treatment.

261

262 METHODS

263 **Cohort.** Individuals with culture-positive pulmonary tuberculosis (TB) were recruited as part of
264 the Kawempe Community Health Study in Kampala, Uganda from 2002 to 2012 as previously
265 described (3, 22). Household contacts of index cases were initially followed for 2 years with
266 serial tuberculin skin test (TST) monitoring (22). A subset of individuals were retraced from
267 2014 and 2017 and re-assessed by TST as well as IFN γ release assays (IGRA) for another 2 years
268 (3). Individuals were classified as concordant negative resisters (RSTR) or concordant positive
269 latent tuberculosis infection (LTBI). All participants were at least 15 years old at the time of
270 retracing, HIV-negative, and gave written, informed consent, approved by the institutional
271 review boards of their associated institution. Cryopreserved peripheral blood mononuclear cells
272 (PBMC) and plasma from a subset of retraced individuals were used here.

273

274 **Cell culture and DNA extraction.** Cryopreserved PBMCs were thawed, washed, and
275 resuspended at 2E6 cells/mL in RPMI-10 supplemented with M-CSF (50 ng/mL), then rested
276 overnight in 6-well non-TC treated dishes. CD14+/CD16+ monocytes were isolated by negative
277 selection magnetic bead column purification (Pan Monocyte Isolation Kit, Miltenyi Biotec). For

278 chromatin accessibility (ATAC-seq), 5x10E4 monocytes were removed and lysed in resuspension
279 buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl₂) plus 0.1% NP40, 0.1% Tween-20, and
280 0.01% digitonin. Cells were lysed on ice for 3 minutes and then washed in resuspension buffer
281 plus 0.1% Tween-20. Nuclei were centrifuged for 10 min at 500xg and 4°C. Supernatant was
282 removed and nuclei were resuspended in 50 µL of transposition mix (Tagment DNA Buffer, 0.1%
283 Tween-20, 0.05% digitonin, 2.5 µL Tagment DNA Enzyme). Transposition reactions were
284 incubated for 30 minutes at 37°C with shaking at 10E3 RPM. DNA fragments were purified with
285 MinElute Reaction kit according to the manufacturer's instructions (Qiagen). For methylation,
286 monocytes were plated at 5x10E5 per well in RPMI-10 supplemented with M-CSF. After 24
287 hours, media was removed, and genomic DNA was isolated using Quick-gDNA MiniPrep kit
288 according to the manufacturer's instructions (Zymo Research).

289
290 **Chromatin accessibility.** DNA from unstimulated monocytes was amplified by PCR for 5 cycles
291 with indexing primer and barcoded primers. Amplicons were purified with the Agencourt
292 AMPure XP Purification Kit (Beckman Coulter) and sequenced using 50 bp paired-end
293 Tn5 transposase-accessible chromatin sequencing (ATAC-seq) on a NovaSeq6000. Sequence
294 quality was assessed using FastQC (v0.11.8 (45)), and sequencing adapters were removed using
295 AdapterRemoval (v2.3.1 (46)). Reads were aligned to the human genome (GRCh38) using STAR
296 (v2.7.5 (47)), and alignments were assessed with Picard (v2.33.3 (48)) and samtools (v1.10 (49)).
297 Peaks were called from alignments using Genrich (v0.6 (50)) with PCR duplicates removed and
298 using the default ATAC-seq mode. Further data cleaning was completed in R (v4.0.2 (51)).
299 Consensus peaks across samples were determined using ChIPQC (v1.24.1 (52)). Blacklisted

300 (5421 (53)), mitochondrial (1), and rare peaks (32537 present in < 10% of samples) were
301 removed. Nucleosome-free reads in peaks were quantified with Rsubread (v2.2.4 (54)) and
302 filtered to peaks on autosomal chromosomes with > 0.1 counts per million (CPM) in at least
303 10% of samples. This resulted in 40919 peaks and 1.3 million \pm 1.1 million s.d. reads per sample.
304 Reads were TMM normalized with edgeR (v3.30.3 (55)) and log2 CPM normalized with limma
305 (v3.44.3 (56)). Peaks were annotated to the human genome using ChIPseeker (v1.24.0 (57)) and
306 the UCSC known gene track for GRCh38 (58).

307

308 **Methylation.** DNA from unstimulated monocytes was bisulfate treated using the EZ-96 DNA
309 Methylation kit (Zymo Research). Bisulfite conversion was confirmed by PCR using Universal
310 Methylated Human DNA Standard with hMLH1 Primers (Zymo Research). Converted DNA was
311 then applied to an Illumina Infinium MethylationEPIC850 BeadChip (865918 probes) and
312 sequenced on a NovaSeq6000. Data cleaning and analysis were performed using ChAMP
313 (v2.18.3 (59)) in R (51). Probes were filtered (59) to remove poor-quality (23907), non-CpG
314 (2860), XY chromosome (16424), and SNP adjacent probes (94347). Beta values for the
315 remaining 728380 probes were normalized using functional normalization, chip bias was
316 removed using Combat, and values were log2 transformed to M values. Probes were annotated
317 to the human genome (hg19) within ChAMP and ported to GRCh38 (60).

318

319 **Kinship.** Kinship was determined as previously described (9). Briefly, genotypes were
320 determined using the Illumina MEGA^{EX} array or Infinium OmniExpress BeadChip as previously
321 reported (44). In PLINK2 (61), SNPs present in both arrays were filtered by Hardy-Weinberg

322 Equilibrium ($P < 1 \times 10^{-6}$), minor allele frequency (MAF > 0.05), call rate (> 0.95), and linkage
323 disequilibrium ($LD R^2 < 0.1$ in 50 bp windows with a 5 bp slide). Pairwise kinship was calculated
324 using the robust King method for identity-by-descent (IBD, SNPRelate v1.22.0 (62)) and a
325 genetic relationship matrix (GRM, GENESIS v2.18.0 (63)) calculated from these 63812 filtered
326 SNPs.

327

328 **Differential analyses.** Differentially methylated probes (DMP) and differentially methylated
329 regions (DMR) were determined in 29 RSTR and 29 LTBI samples with complete methylation
330 and kinship data. Differentially accessible regions (DAR) were determined for 29 RSTR and 31
331 LTBI with complete chromatin accessibility and kinship data. DMP and DAR were assessed with
332 kimma (v1.4.4 (64)) using a linear mixed effects model of RSTR vs LTBI corrected for age, sex,
333 and kinship. Genetic kinship was included to account for closely related household contacts,
334 and it improved model fit as assessed by sigma (Figure S1A). Sex and age were included as co-
335 variates as they improved model fit for some sites (Figure S1B) and were significant for many
336 sites (Figure S1C,D). Additional co-variates including body mass index (BMI), tuberculosis
337 exposure score (3), and BCG vaccination scar were removed due to missing data, lack of
338 significance, or no improvement in model fit assessed by residual sigma.

339

340 DMP model estimates were then used to determine differentially methylation regions (DMR) in
341 DMRcate (v2.2.1 (65)) with settings recommended in (66) (min probes = 2, lambda = 500 bp,
342 scaling = 5). DMR were assessed at FDR < 1E-70, a slight relaxation of DMRcate's default cutoff
343 of 8.16E-85, which was determined based on the rate of DMP within the data set.

344

345 **Gene enrichment.** Epigenetic sites were annotated to hg38 genes based on overlap with intron,
346 exon, untranslated region (UTR), or promoters defined as within 1500 bp of the transcription
347 start site (TSS1500). DAR were annotated using ChIPseeker, DMP using the Infinium hg38
348 manifest (60), and DMR using DMRcate. Genes were queried for enrichment in Broad MSigDB
349 (23) Hallmark (H) and gene ontology biological process (C5 GO BP) gene-sets using
350 hypergeometric enrichment with SEARchways (v1.0.0). Gene-sets with FDR < 0.2 and > 4%
351 enrichment (k/K) were considered significant. Gene ontology term similarity was visualized by
352 semantic similarity using rrvgo implementing GOSemSim (67). DAR genes were not assessed
353 due to the small number of associated genes.

354

355 **Gene expression.** Previously, Ugandan RSTR and LTBI monocyte gene expression was profiled
356 with and without 6-hour Mtb infection (9). Differentially expressed genes (DEGs) were defined
357 for the Mtb:RSTR interaction term in a model of Mtb*RSTR corrected for age, sex, sequencing
358 batch, and genetic kinship. This original model was used for ABCA1 expression in the present
359 study. Since several methylation genes of interest did not meet the original study's gene
360 expression cutoff (1 CPM in at least 5% of samples), an additional targeted analysis of these
361 genes was performed. Here, all genes with > 0 CPM in at least 1 sample were obtained and log2
362 counts per million (CPM) were calculated. Genes of interest (APOC3, CIT, KCNQ1, PLA2G3,
363 SHANK2) were modeled using the same interaction model as the original study, and significant
364 genes were defined at Benjamini-Hochberg FDR < 0.2. In addition, targeted gene-set
365 enrichment analysis (GSEA (68)) was performed for the 11 MSigDB gene-sets that were

366 significantly enriched in methylation genes. Gene-level fold change estimates were extracted
367 from the original linear mixed effects model for the four Mtb:RSTR contrasts (e.g. Mtb vs media
368 in RSTR, RSTR vs LTBI in media, etc). Significant enrichment using GSEA was defined at $P < 0.05$.

369

370 **Monocyte-derived macrophages (MDM) stimulated with IFN.** Additional analyses were
371 performed with a previously published RNA-seq data set of human MDM stimulated with
372 $\text{IFN}\alpha 8$, $\text{IFN}\beta$, $\text{IFN}\epsilon$, or $\text{IFN}\gamma$ (24). Briefly, MDMs isolated from 5 healthy donors were treated with
373 recombinant interferons for 6 hours. Total RNA was extracted and sequenced as described (24).

374 In this study, linear mixed effects model fold change estimates of IFN-stimulated expression vs
375 unstimulated controls were used in GSEA (68) of the 11 MSigDB gene-sets that were
376 significantly enriched in methylation genes. Significant enrichment using GSEA was defined at P
377 < 0.05 .

378

379 **Cholesterol efflux capacity.** Cholesterol efflux capacity (CEC) was measured in serum from 41
380 RSTR and 43 LTBI. CEC of serum HDL was quantified using J774 murine macrophages (ATCC) to
381 measure total CEC and baby hamster kidney fibroblast (BHK) cells transfected with a
382 mifepristone inducible ABCA1 transporter to measure ABCA1-specific CEC as previously
383 described (69, 70). In short, serum from RSTR and LTBI was reconstituted from freshly thawed
384 plasma, and polyethylene glycol (20% PEG8000, 2:5 v/v) was added to precipitate apoB-
385 containing (non-HDL) lipoproteins. After centrifugation, supernatants containing HDL (serum
386 HDL) were incubated for 4 hours with unstimulated or stimulated cells labeled with
387 radiolabeled [^3H]-cholesterol (71). For J774 macrophages, the cells were stimulated with cAMP

388 to activate the cells including induction of ABCA1 expression. For BHK cells, stimulation was
389 completed with 0.01 μ M mifepristone to specifically induce expression of the ABCA1
390 transporter. Thus, the J774 cell model captures overall efflux of cholesterol through multiple
391 pathways, including ABCA1, while the ABCA1-BHK model specifically measures cholesterol
392 efflux through the ABCA1 pathway.

393
394 For both J774 and BHK cells, HDL CEC (percent total cholesterol effluxed from cells to HDL) was
395 determined as the ratio of radio-labeled cholesterol in the media at the end of the incubation
396 relative to the total in the system (media + cell pellet). For BHK cells, ABCA1-specific efflux was
397 calculated as the difference in the percent efflux between stimulated cells more highly
398 expressing ABCA1 versus unstimulated cells. Total CEC and ABCA1-specific CEC were compared
399 in RSTR and LTBI in a linear mixed effects model corrected for age, sex, and BMI using kimma
400 (64). Significance was evaluated at $P < 0.05$.

401
402 **HDL particle concentration and size.** HDL was assessed for the same participants as CEC. Total
403 lipoprotein fraction was separated from plasma proteins by a single step density
404 ultracentrifugation of EDTA plasma as described previously (72, 73). HDL particle concentration
405 and size were quantified by calibrated differential ion mobility analysis on a differential mobility
406 analyzer (DMA) (TSI Inc., MN) as described previously (72, 73). Six HDL subspecies (extra small,
407 small, medium, medium large, large, extra-large) were fitted to the DMA profiles by
408 unsupervised, iterative curve-fitting using Fityk (74). Because DMA directly quantifies the
409 number of particles, areas under the curve fitted for each subspecies were directly converted to

410 HDL particle concentration using a calibration curve constructed with a protein standard. For
411 total HDL particle concentration, intra-day and inter-day coefficients of variation (CV) were <
412 10%. For individual species, CV were < 10% with the exception of xsHDL and sHDL (14.8 and
413 18.5%, respectively). HDL concentration and size were compared in RSTR and LTBI in a linear
414 mixed effects model corrected for age, sex, and BMI using kimma (64). Significance was
415 evaluated at FDR < 0.2.

416

417 **Data availability.** Access to raw epigenetic and transcriptomic data for the Uganda cohort is
418 available through the NCBI database of Genotypes and Phenotypes (dbGaP) Data Browser
419 (<https://www.ncbi.nlm.nih.gov/gap/>) under accession 002445.v3.p1 but first must be approved
420 by the data access committee (DAC) for the study site (see Supplemental Methods in (9)). Data
421 related to the MDM-IFN experiment are available in the Gene Expression Omnibus (GEO)
422 GSE236156. Scripts for this manuscript are available at https://github.com/hawn-lab/RSTR_epigenetics_public

424

425 **FUNDING**

426 This study was supported by NIH grants K08AI143926 and T32AI007044 (to JDS), R01AI124348
427 (to WHB, TRH, CMS, HMK), U01AI115642 (to WHB, TRH, CMS, and HMK), R33AI138272 (to TRH,
428 WHB, HMK, CMS), K24AI137310 (to TRH). Additionally, this work was support by the Bill and
429 Melinda Gates Foundation grant OPP1151836 (to TRH, WHB, CMS and HMK) and Proteomics
430 and Bioinformatics Core of Diabetes Research Center NIH grant P30 DK017047 (to TV).

431

432 **ACKNOWLEDGEMENTS**

433 We thank the individual study participants of the Kawempe Community Health Study, study
434 coordinators and the clinical and research staff including LaShaunda Malone, Keith Chervenak,
435 Marla Manning, Dr. Alphonse Okwera, Dr. Moses Joloba, Hussein Kisingo, Sophie Nalukwago,
436 Dorcas Lamunu, Deborah Nsamba, Annet Kawuma, Saidah Menya, Joan Nassuna, Joy Beseke,
437 Michael Odie, Henry Kawoya, and Bonnie Thiel.

438

439 **TABLES**

440 Table 1.

		Chromatin accessibility	RSTR vs LTBI p-value ^a	Methylation	RSTR vs LTBI p-value ^a
Pass-filter donors with kinship	RSTR	29	NA	29	NA
	LTBI	31		29	
Female, %		46.7	1	50.0	1
Age at enrollment, yrs		16.7 ± 12.2	0.48	17.2 ± 12.6	0.44
Age at sampling, yrs		25.0 ± 11.7	0.40	25.8 ± 12.3	0.32
BMI		22.6 ± 4.4	0.61	22.9 ± 4.3	0.56
BCG scar, %		60.0	0.50	56.9	0.26
HIV+, %		0	NA	0	NA
TB exposure score at enrollment		6.2 ± 1.2	0.49	6.1 ± 1.2	0.91
Relatedness ^b					
Mean 3° and closer per person		0.13 ± 0.34	0.92	0.10 ± 0.31	0.40
Mean 1° and closer per person		0.63 ± 0.92	0.86	0.55 ± 0.88	0.77

441 ^a Continuous metrics expressed at mean ± standard deviation (sd) and tested by t-test.

442 Categorical metrics expressed as percentages and tested by Chi-squared. ^b Relatedness was

443 measured as the total number of first-degree relationships (kinship > 0.5) and third-degree or
444 closer relationships (kinship > 0.125) per person, then summarized as mean \pm sd across all
445 individuals. BMI: body mass index, BCG: bacille Calmette-Guerin

446 **FIGURE LEGENDS**

447 **Figure 1. Monocyte epigenetic sites associated with RSTR vs LTBI.** Genome-wide methylation
448 and chromatin accessibility were assessed in unstimulated monocytes. RSTR and LTBI were
449 compared using a mixed effects model corrected for age, sex, and kinship. (A) Differentially
450 accessible chromatin regions (DAR, N = 40,919) were measured using log2 counts per million
451 (CPM) reads in open chromatin peaks. (B) Differentially methylated probes (DMP, N = 728,380)
452 and (C) differentially methylated DMRcate regions (DMR, N = 63) were measured using log2 M
453 values. Significant hits are defined as FDR < 0.2 for DAR and DMP (solid line) or FDR < 1E-70 for
454 DMR (dashed line). This resulted in 2 DAR, 174 DMP, and 63 DMR significantly different
455 between RSTR and LTBI.

456

457 **Figure 2. Pathways and genes with differentially methylated regions in RSTR and LTBI**
458 **monocytes.** Differentially methylated regions (DMR) were analyzed with hypergeometric mean
459 pathway enrichment analysis with Broad MSigDB gene sets. (A) Gene ontology gene sets
460 significantly enriched in DMR (FDR < 0.2 and k/K > 0.04). Gene sets visualized by semantic
461 similarity in MDS space. Each dot is a gene set with size indicating percent enrichment (k/K *
462 100) and colors grouping similar terms. (B) DMR genes within significant GO gene sets. Colored
463 boxes indicate presence in gene sets as in (A). Fold changes of probes in differentially
464 methylated regions (DMR) are indicated by + positive for all probes, - negative for all probes,
465 and -/+ variable across probes with the mean region trend in parentheses.

466

467 **Figure 3. Methylation regions associated with significantly enriched gene sets in RSTR and**
468 **LTBI monocytes.** Genes annotated to differentially methylated regions (DMR, FDR < 1E-70)
469 were assessed for enrichment in gene ontology (GO) gene sets. DMR associated with
470 significantly enriched gene sets (FDR < 0.2) are grouped by (A,B,E) Ss or (C,D,F) Hippo signaling
471 associated genes. The 3 DMR in other enriched pathways (Figure 2B) are not shown. (A,C) Log2
472 M values for each probe in a DMR are shown with standard deviation error shading for LTBI
473 (orange) and RSTR (purple). Significant individual probes (DMP) are indicated with * (FDR < 0.2).
474 (B,D) DMRs annotated to their nearest gene. Grey arrows indicate full gene transcripts, and
475 black boxes are DMRs. SHANK2 includes DMR 20 and DMR 59 that are too close to be resolved
476 in (D). (E,F) Log2 normalized gene expression in RSTR and LTBI monocytes with and without
477 Mtb infection. FDR indicates the Mtb vs media comparison (FDR < 0.2). No genes were
478 significant for the main effect RSTR vs LTBI or the interaction of Mtb:RSTR (FDR > 0.2).

479
480 **Figure 4. Mtb and IFN stimulated gene expression in gene sets enriched for RSTR methylation**
481 **signature.** Gene set enrichment analysis (GSEA) was performed for pathways that were
482 significantly enriched for DMR annotated genes (N = 63 genes, Figure 2). Fold change estimates
483 were used from mixed effects models run on one of two RNAseq data sets. (A) GSEA for Mtb
484 and RSTR contrasts. Monocytes from RSTR and LTBI were infected with Mtb for 6 hours, and
485 gene expression was modeled for the interaction of Mtb and RSTR status (Mtb:RSTR) corrected
486 for age, sex, kinship, and sequencing batch. Contrast fold changes were compared for Mtb
487 infection vs media within RSTR or LTBI as well as RSTR vs LTBI within media or Mtb infected
488 groups. Significant enrichment is indicated in red ($P < 0.05$). (B) GSEA for IFN stimulation. MDMs

489 from healthy donors were stimulated with type I and II interferons for 6 hrs. Gene expression
490 was modeled for IFN vs media. (C) All genes in the GO gene set “lipid export from cell” are
491 visualized in the STRING protein-protein interaction network. Color indicates leading-edge GSEA
492 and significant DMR genes. Leading-edge genes include +Mtb vs media in RSTR and/or LTBI
493 (Mtb), RSTR vs LTBI in Mtb-infected samples (RSTR), and IFN α 8 stimulation vs media (IFN α 8).
494 Genes that were leading edge in non-significant IFN β , IFN ϵ , and IFN γ GSEA are grouped in “IFN
495 other”. Genes annotated to a significant DMR are additionally colored (DMR gene). Edge width
496 indicates STRING combined score with only scores > 400 shown. (D) GO “Hippo signaling” gene
497 set genes are similarly represented, except leading-edge genes for IFN γ are colored and non-
498 significant “IFN other” includes IFN α 8, IFN β , and IFN ϵ .

499

500 **Figure 5. Total and ABCA1-specific cholesterol efflux capacity in RSTR and LTBI.** Cholesterol
501 efflux capacity (CEC) was measured in serum-derived HDL from RSTR and LTBI participants.
502 Serum HDL was incubated for 4 hours with unstimulated or stimulated [3 H]-cholesterol labeled
503 cells. CEC was calculated as percent cholesterol in media versus total (media + cell pellet). RSTR
504 and LTBI were compared using a linear model corrected for age sex, and body mass index
505 (BMI). (A) Total CEC from J774 cells was measured after exposure to RSTR and LTBI serum HDL.
506 Macrophages were stimulated with cAMP to increase CEC. (B) CEC in ABCA1-transfected BHK
507 cells with RSTR and LTBI HDL. ABCA1-transfected BHK cells were stimulated with media or
508 mifepristone to induce ABCA1 expression. ABCA1-specific CEC was calculated as stimulated
509 (ABCA1 expressing) BHK minus unstimulated. (C) ABCA1 gene expression in monocytes with and
510 without Mtb infection ⁹. RSTR and LTBI monocytes were cultured with and without Mtb

511 infection for 6 hrs. Gene expression was modeled for the interaction between Mtb infection
512 and RSTR status (Mtb:RSTR). Significant Mtb:RSTR contrasts are labeled by FDR (FDR < 0.2).

513 REFERENCES

- 514 1. World Health Organization. 2020. Global tuberculosis report. Geneva.
- 515 2. Houben RMGJ, Dodd PJ. 2016. The Global Burden of Latent Tuberculosis Infection: A
516 Re-estimation Using Mathematical Modelling. *PLoS Med* 13:e1002152.
- 517 3. Stein CM, Nsereko M, Malone LL, Okware B, Kisingo H, Nalukwago S, Chervenak K,
518 Mayanja-Kizza H, Hawn TR, Boom WH. 2019. Long-term Stability of Resistance to
519 Latent *Mycobacterium tuberculosis* Infection in Highly Exposed Tuberculosis Household
520 Contacts in Kampala, Uganda. *Clin Infect Dis* 68:1705–1712.
- 521 4. Mave V, Chandrasekaran P, Chavan A, Shivakumar SVBY, Danasekaran K, Paradkar M,
522 Thiruvengadam K, Kinikar A, Murali L, Gaikwad S, Hanna LE, Kulkarni V, Pattabiraman
523 S, Suryavanshi N, Thomas B, Kohli R, Sivaramakrishnan GN, Pradhan N, Bhanu B,
524 Kagal A, Golub J, Gandhi N, Gupte A, Gupte N, Swaminathan S, Gupta A. 2019.
525 Infection free “resisters” among household contacts of adult pulmonary tuberculosis.
526 *PLoS One* 14:e0218034.
- 527 5. Medawar L, Tukiman HM, Mbayo G, Donkor S, Owolabi O, Sutherland JS. 2019.
528 Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and
529 reverters in the Gambia. *Immun Inflamm Dis* 7:260–270.
- 530 6. Verrall AJ, Alisjahbana B, Apriani L, Novianty N, Nurani AC, van Laarhoven A, Ussher
531 JE, Indrati A, Ruslami R, Netea MG, Sharples K, van Crevel R, Hill PC. 2020. Early
532 Clearance of *Mycobacterium tuberculosis*: The INFECT Case Contact Cohort Study in
533 Indonesia. *J Infect Dis* 221:1351–1360.
- 534 7. Berrington WR, Hawn TR. 2007. *Mycobacterium tuberculosis*, macrophages, and the
535 innate immune response: does common variation matter? *Immunol Rev* 219:167–186.
- 536 8. Simmons JD, Van PT, Stein CM, Chihota V, Ntshiqwa T, Maenetje P, Peterson GJ,
537 Reynolds A, Benchek P, Velen K, Fielding KL, Grant AD, Graustein AD, Nguyen FK,
538 Seshadri C, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn
539 TR. 2021. Monocyte metabolic transcriptional programs associate with resistance to
540 tuberculin skin test/interferon- γ release assay conversion. *J Clin Invest* 131.
- 541 9. Simmons JD, Dill-McFarland KA, Stein CM, Van PT, Violet C, Thobani N, Pholo M,
542 Peterson GJ, Penelope B, Mary N, Kavindhran V, Fielding KL, Grant AD, Raphael G,
543 Harriet M-K, Wallis RS, Gavin C, Henry BW, Hawn TR. 2022. Monocyte Transcriptional
544 Responses to *Mycobacterium tuberculosis* Associate with Resistance to Tuberculin Skin
545 Test and Interferon Gamma Release Assay Conversion. *mSphere* 7:e00159-22.
- 546 10. Karlsson L, Das J, Nilsson M, Tyrén A, Pehrson I, Idh N, Sayyab S, Paues J, Ugarte-Gil
547 C, Méndez-Aranda M, Lerm M. 2021. A differential DNA methylome signature of
548 pulmonary immune cells from individuals converting to latent tuberculosis infection. *Sci
549 Rep* 11:19418.
- 550 11. Pehrson I, Sayyab S, Das J, Idh N, Paues J, Méndez-Aranda M, Ugarte-Gil C, Lerm M.
551 2022. The spectrum of tuberculosis described as differential DNA methylation patterns in
552 alveolar macrophages and alveolar T cells. *Clin Epigenetics* 14:175.
- 553 12. Verma D, Parasa VR, Raffetseder J, Martis M, Mehta RB, Netea M, Lerm M. 2017. Anti-
554 mycobacterial activity correlates with altered DNA methylation pattern in immune cells
555 from BCG-vaccinated subjects. *Sci Rep* 7:12305.
- 556 13. Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, Tzelepis F, Pernet E,
557 Dumaine A, Grenier J-C, Mailhot-Léonard F, Ahmed E, Belle J, Besla R, Mazer B, King

558 IL, Nijnik A, Robbins CS, Barreiro LB, Divangahi M. 2018. BCG Educates
559 Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis.
560 *Cell* 172:176-190.e19.

561 14. Braian C, Karlsson L, Das J, Lerm M. 2023. Selected β -Glucans Act as Immune-Training
562 Agents by Improving Anti-Mycobacterial Activity in Human Macrophages: A Pilot Study.
563 *J Innate Immun* 15:751–764.

564 15. Das J, Verma D, Gustafsson M, Lerm M. 2019. Identification of DNA methylation
565 patterns predisposing for an efficient response to BCG vaccination in healthy BCG-naïve
566 subjects. *Epigenetics* 14:589–601.

567 16. Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, Sherman DR,
568 Gerner MY, Urdahl KB. 2018. Alveolar Macrophages Provide an Early *Mycobacterium*
569 tuberculosis Niche and Initiate Dissemination. *Cell Host Microbe* 2018/08/23. 24:439–
570 446.e4.

571 17. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, Schurr E, Wallis RS,
572 Churchyard G, Mayanja-Kizza H, Boom WH, Hawn TR. 2018. Immunological
573 mechanisms of human resistance to persistent *Mycobacterium* tuberculosis infection. *Nat Rev Immunol* 18:575–589.

575 18. Looney M, Lorenc R, Halushka MK, Karakousis PC. 2021. Key Macrophage Responses
576 to Infection With *Mycobacterium* tuberculosis Are Co-Regulated by microRNAs and
577 DNA Methylation. *Front Immunol* 12.

578 19. Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, Kleinnijenhuis J,
579 Lachmandas E, Gonçalves LG, Belinha A, Cunha C, Oosting M, Joosten LAB, Matarese
580 G, van Crevel R, Netea MG. 2016. Immunometabolic Pathways in BCG-Induced Trained
581 Immunity. *Cell Rep* 17:2562–2571.

582 20. Seshadri C, Sedaghat N, Campo M, Peterson G, Wells RD, Olson GS, Sherman DR, Stein
583 CM, Mayanja-Kizza H, Shojaie A, Boom WH, Hawn TR. 2017. Transcriptional networks
584 are associated with resistance to *Mycobacterium* tuberculosis infection. *PLoS One*
585 12:e0175844.

586 21. Campo M, Heater S, Peterson GJ, Simmons JD, Skerrett SJ, Mayanja-Kizza H, Stein CM,
587 Boom WH, Hawn TR. 2021. HDAC3 inhibitor RGFP966 controls bacterial growth and
588 modulates macrophage signaling during *Mycobacterium* tuberculosis infection.
589 *Tuberculosis* 127.

590 22. Stein CM, Zalwango S, Malone LL, Thiel B, Mupere E, Nsereko M, Okware B, Kisingo
591 H, Lancioni CL, Bark CM, Whalen CC, Joloba ML, Boom WH, Mayanja-Kizza H. 2018.
592 Resistance and Susceptibility to *Mycobacterium* tuberculosis Infection and Disease in
593 Tuberculosis Households in Kampala, Uganda. *Am J Epidemiol* 187:1477–1489.

594 23. Dolgalev I. 2019. msigdbr: MSigDB Gene Sets for Multiple Organisms in a Tidy Data
595 Format. 7.0.1.

596 24. Campo M, Dill-McFarland K, Peterson G, Benson B, Skerrett S, Hawn T. 2024. Human
597 alveolar and monocyte-derived human macrophage responses to *Mycobacterium*
598 tuberculosis. *bioRxiv* 2024.02.20.581265.

599 25. Aylon Y, Oren M. 2016. The Hippo pathway, p53 and cholesterol. *Cell Cycle* 15:2248–
600 2255.

601 26. Laval T, Chaumont L, Demangel C. 2021. Not too fat to fight: The emerging role of
602 macrophage fatty acid metabolism in immunity to *Mycobacterium* tuberculosis. *Immunol Rev*
603 301:84–97.

604 27. Sato H, Kato R, Isogai Y, Saka G, Ohtsuki M, Taketomi Y, Yamamoto K, Tsutsumi K,
605 Yamada J, Masuda S, Ishikawa Y, Ishii T, Kobayashi T, Ikeda K, Taguchi R, Hatakeyama
606 S, Hara S, Kudo I, Itabe H, Murakami M. 2008. Analyses of group III secreted
607 phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma
608 lipoprotein modification, macrophage foam cell formation, and atherosclerosis. *J Biol
609 Chem* 283:33483–33497.

610 28. Calkin AC, Tontonoz P. 2012. Transcriptional integration of metabolism by the nuclear
611 sterol-activated receptors LXR and FXR. *Nat Rev Mol Cell Biol* 13:213–224.

612 29. Luo M, Liu A, Wang S, Wang T, Hu D, Wu S, Peng D. 2017. ApoCIII enrichment in
613 HDL impairs HDL-mediated cholesterol efflux capacity. *Sci Rep* 7:2312.

614 30. Chen X, Yang Y, Li S, Peng Q, Zheng L, Jin L, Wang X. 2012. Several Polymorphisms of
615 KCNQ1 Gene Are Associated with Plasma Lipid Levels in General Chinese Populations.
616 *PLoS One* 7:e34229-.

617 31. Yu X-H, Deng W-Y, Chen J-J, Xu X-D, Liu X-X, Chen L, Shi M-W, Liu Q-X, Tao M,
618 Ren K. 2020. LncRNA kcnq1ot1 promotes lipid accumulation and accelerates
619 atherosclerosis via functioning as a ceRNA through the miR-452-3p/HDAC3/ABCA1
620 axis. *Cell Death Dis* 11:1043.

621 32. Peyron P, Vaubourgeix J, Poquet Y, Levillain F, Botanch C, Bardou F, Daffé M, Emile J-
622 F, Marchou B, Cardona P-J, de Chastellier C, Altare F. 2008. Foamy Macrophages from
623 Tuberculous Patients' Granulomas Constitute a Nutrient-Rich Reservoir for M.
624 tuberculosis Persistence. *PLoS Pathog* 4:e1000204-.

625 33. Chandra P, Couillon H, Agarwal M, Goss CW, Philips JA. 2022. Macrophage global
626 metabolomics identifies cholestenone as host/pathogen cometabolite present in human
627 *Mycobacterium tuberculosis* infection. *J Clin Invest* 132.

628 34. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host
629 cholesterol. *Proceedings of the National Academy of Sciences* 105:4376–4380.

630 35. Simmons JD, Van PT, Stein CM, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ,
631 Reynolds A, Benchek P, Velen K, Fielding KL, Grant AD, Graustein AD, Nguyen FK,
632 Seshadri C, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn
633 TR. 2021. Monocyte metabolic transcriptional programs associate with resistance to
634 tuberculin skin test/interferon- γ release assay conversion. *J Clin Invest* 131.

635 36. Gatfield J, Pieters J. 2000. Essential Role for Cholesterol in Entry of Mycobacteria into
636 Macrophages. *Science* (1979) 288:1647–1651.

637 37. Russell DG, Cardona P-J, Kim M-J, Allain S, Altare F. 2009. Foamy macrophages and the
638 progression of the human tuberculosis granuloma. *Nat Immunol* 10:943–948.

639 38. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KVS. 2012. *Mycobacterium*
640 tuberculosis-Driven Targeted Recalibration of Macrophage Lipid Homeostasis Promotes
641 the Foamy Phenotype. *Cell Host Microbe* 12:669–681.

642 39. Liu Y, An Y, Li G, Wang S. 2023. Regulatory mechanism of macrophage polarization
643 based on Hippo pathway. *Front Immunol* 14.

644 40. Pawełczyk J, Brzostek A, Minias A, Płociński P, Rumijowska-Galewicz A, Strapagiel D,
645 Zakrzewska-Czerwińska J, Dziadek J. 2021. Cholesterol-dependent transcriptome
646 remodeling reveals new insight into the contribution of cholesterol to *Mycobacterium*
647 tuberculosis pathogenesis. *Sci Rep* 11:12396.

648 41. Mazzzone R, Zwergel C, Artico M, Taurone S, Ralli M, Greco A, Mai A. 2019. The
649 emerging role of epigenetics in human autoimmune disorders. *Clin Epigenetics* 11:34.

650 42. Ehrlich M. 2002. DNA methylation in cancer: too much, but also too little. *Oncogene* 21:5400–5413.

651 43. Talens RP, Christensen K, Putter H, Willemsen G, Christiansen L, Kremer D, Suchiman HED, Slagboom PE, Boomsma DI, Heijmans BT. 2012. Epigenetic variation during the adult lifespan: cross-sectional and longitudinal data on monozygotic twin pairs. *Aging Cell* 11:694–703.

652 44. McHenry ML, Benchek P, Malone L, Nsereko M, Mayanja-Kizza H, Boom WH, Williams SM, Hawn TR, Stein CM. 2021. Resistance to TST/IGRA conversion in Uganda: Heritability and Genome-Wide Association Study. *EBioMedicine* 74.

653 45. Andrews S, Krueger F, Segonds-Pichon Anne, Biggins L, Krueger C, Wingett S. 2012. FastQC: A Quality Control Tool for High Throughput Sequence Data. Babraham, UK.

654 46. Schubert M, Lindgreen S, Orlando L. 2016. AdapterRemoval v2: rapid adapter trimming, identification, and read merging. *BMC Res Notes* 9:88.

655 47. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2012/10/25. 29:15–21.

656 48. Broad Institute. 2019. Picard Toolkit. 2.18.7. Broad Institute, GitHub repository. Broad Institute.

657 49. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Subgroup 1000 Genome Project Data Processing. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009/06/08. 25:2078–2079.

658 50. Gaspar JM. 2018. Genrich. 0.6.

659 51. R Core Team. 2023. R: A language and environment for statistical computing. 4.2.1. R Foundation for Statistical Computing, Vienna, Austria.

660 52. Carroll TS, Liang Z, Salama R, Stark R, de Santiago I. 2014. Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data. *Front Genet* 5:75.

661 53. Amemiya HM, Kundaje A, Boyle AP. 2019. The ENCODE Blacklist: Identification of Problematic Regions of the Genome. *Sci Rep* 9:9354.

662 54. Liao Y, Smyth GK, Shi W. 2019. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* 47:e47–e47.

663 55. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2009/11/11. 26:139–140.

664 56. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* 43:e47.

665 57. Yu G, Wang L-G, He Q-Y. 2015. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics* 31:2382–2383.

666 58. Kuhn RM, Haussler D, Kent WJ. 2013. The UCSC genome browser and associated tools. *Brief Bioinform* 2012/08/20. 14:144–161.

667 59. Tian Y, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, Teschendorff AE. 2017. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. *Bioinformatics* 33:3982–3984.

694 60. Zhou W, Laird PW, Shen H. 2016. Comprehensive characterization, annotation and
695 innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res*
696 45:e22–e22.

697 61. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. 2015. Second-
698 generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4.

699 62. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. 2012. A high-performance
700 computing toolset for relatedness and principal component analysis of SNP data.
701 *Bioinformatics* 2012/10/11. 28:3326–3328.

702 63. Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, Rice KM, Conomos MP.
703 2019. Genetic association testing using the GENESIS R/Bioconductor package.
704 *Bioinformatics* 35:5346–5348.

705 64. Dill-McFarland KA, Mitchell K, Batchu S, Segnitz RM, Benson B, Janczyk T, Cox MS,
706 Mayanja-Kizza H, Boom WH, Benchek P, Stein CM, Hawn TR, Altman MC. 2023.
707 Kimma: flexible linear mixed effects modeling with kinship covariance for RNA-seq data.
708 *Bioinformatics* 39:btad279.

709 65. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, V Lord R, Clark SJ, Molloy
710 PL. 2015. De novo identification of differentially methylated regions in the human
711 genome. *Epigenetics Chromatin* 8:6.

712 66. Mallik S, Odom GJ, Gao Z, Gomez L, Chen X, Wang L. 2019. An evaluation of
713 supervised methods for identifying differentially methylated regions in Illumina
714 methylation arrays. *Brief Bioinform* 20:2224–2235.

715 67. Yu G, Li F, Qin Y, Bo X, Wu Y, Wang S. 2010. GOSemSim: an R package for measuring
716 semantic similarity among GO terms and gene products. *Bioinformatics* 26:976–978.

717 68. Korotkevich G, Sukhov V, Sergushichev A. 2019. Fast gene set enrichment analysis.
718 *bioRxiv* 60012.

719 69. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH.
720 2010. The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum
721 Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol
722 From Macrophages. *Arterioscler Thromb Vasc Biol* 30:796–801.


723 70. Vaisar T, Gordon JL, Wimberger J, Heinecke JW, Hinderliter AL, Rubinow DR, Girdler
724 SS, Rubinow KB. 2021. Perimenopausal transdermal estradiol replacement reduces serum
725 HDL cholesterol efflux capacity but improves cardiovascular risk factors. *J Clin Lipidol*
726 15:151–161.e0.


727 71. Ronsein GE, Hutchins PM, Isquith D, Vaisar T, Zhao X-Q, Heinecke JW. 2016. Niacin
728 Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux
729 Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
730 *Arterioscler Thromb Vasc Biol* 36:404–411.

731 72. Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y, Anantharamaiah
732 GM, Kim DS, Ranchalis JE, Jarvik GP, Vaisar T, Heinecke JW. 2014. Quantification of
733 HDL Particle Concentration by Calibrated Ion Mobility Analysis. *Clin Chem* 60:1393–
734 1401.














735 73. Vaisar T, Kanter JE, Wimberger J, Irwin AD, Gauthier J, Wolfson E, Bahnam V, Wu I-H,
736 Shah H, Keenan HA, Greenbaum CJ, King GL, Heinecke JW, Bornfeldt KE. 2019. High
737 Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1
738 Associate With Protection From Vascular Complications in People With Long-standing
739 Type 1 Diabetes. *Diabetes Care* 43:178–186.

740 74. Wojdyr M. 2010. Fityk: a general-purpose peak fitting program. *J Appl Crystallogr*
741 43:1126–1128.
742




A**B**


Gene	FA	HDL	Hippo	Lipid	Other	Annotation	DMR	Total probes	Log2 M fold change RSTR - LTBI
APOC3	FA	HDL				TSS1500	DMR 25	2	+
RPTOR					intron		DMR 18	2	+
PER3					intron		DMR 37	4	-
PLA2G3	FA	HDL		Lipid		TSS1500/5'UTR	DMR 49	5	-
SHANK2			intron				DMR 20	3	-
SHANK2			intron				DMR 59	6	-
CIT					TSS1500/exon		DMR 62	7	-/+ (+)
KCNQ1				Lipid	intron	TSS1500	DMR 61	6	-/+ (+)
MCM2					intron		DMR 10	2	-/+ (+)

A**DMR 61 (TSS1500)****DMR 49 (TSS1500/5'UTR)****B****C****DMR 20 (intron)****DMR 59 (intron)****D****E****F**


● LTBI
● RSTR



A



B



C

